Phospho-KCND2 (S616) Antibody

What is KCND2/Kv4.2 and why is phosphorylation at S616 significant?

KCND2 encodes the Kv4.2 channel, a voltage-gated potassium channel that plays a critical role in regulating neuronal excitability, particularly in hippocampal neurons. The phosphorylation of Kv4.2 at serine 616 (S616) is one of three key ERK1/2 phosphorylation sites identified in the cytoplasmic C-terminus of the channel protein, along with T602 and T607 . This phosphorylation site is significant because it represents a convergence point for multiple signaling pathways that regulate channel function and trafficking.

ERK1/2-mediated phosphorylation of Kv4.2 at S616 modulates the channel's electrophysiological properties and has been implicated in neuronal plasticity processes. Unlike phosphorylation by PKA at S552, which primarily affects channel trafficking, ERK1/2 phosphorylation at sites including S616 appears to have more complex effects on channel function that are still being fully characterized .

What signaling pathways lead to Kv4.2 phosphorylation at S616?

Multiple signaling cascades converge to regulate phosphorylation of Kv4.2 at S616, with studies highlighting the following pathways:

• PACAP/PAC1 receptor activation pathway: PACAP (pituitary adenylate cyclase-activating polypeptide) binding to PAC1 receptors activates ERK1/2, which then phosphorylates Kv4.2 at S616 and other sites .

• Ras-dependent signaling: Research demonstrates that dominant-negative Ras (N17-Ras) completely attenuates PACAP38-induced ERK1/2 phosphorylation, indicating that Ras is an essential component upstream of ERK1/2 activation leading to Kv4.2 phosphorylation .

• Arrestin-2-dependent signaling: For certain PAC1 receptor isoforms (specifically Hop1 and Hop2), arrestin-2 is required for PACAP-induced ERK1/2 activation, while the Null isoform can signal independently of arrestin-2 .

• PKC-dependent pathway: All PAC1 isoforms utilize PKC-Ras-MEK1/2 signaling to activate ERK1/2, which then phosphorylates Kv4.2 at S616 .

This complex network of signaling pathways provides multiple regulatory inputs that can modulate Kv4.2 phosphorylation depending on cellular context and physiological state.

How can I detect phosphorylation of Kv4.2 at S616 in neuronal samples?

Detection of phosphorylated Kv4.2 at S616 can be achieved through several complementary methods:

• Metabolic 32P-labeling: This approach involves incubating cultured hippocampal neurons with 32P-labeled orthophosphate, followed by immunoprecipitation with anti-Kv4.2 antibodies and analysis by phosphorimaging and immunoblotting. This technique provides a quantitative measure of total Kv4.2 phosphorylation .

• Phospho-specific antibodies: Using antibodies specifically targeting the phosphorylated S616 site on Kv4.2. For optimal results, validation of antibody specificity using phospho-null mutants (S616A) is recommended .

• Immunoprecipitation followed by immunoblotting: This approach allows for isolation of Kv4.2 channels and subsequent detection of phosphorylated residues using phospho-specific antibodies .

For any of these methods, appropriate controls should include phosphatase inhibitors during sample preparation and comparison with either untreated samples or samples treated with specific pathway activators like PACAP38 or forskolin .

How do different PAC1 receptor isoforms differentially regulate Kv4.2 phosphorylation at S616?

PAC1 receptor exists in multiple splice variants/isoforms, including Null, Hop1, and Hop2, which exhibit distinct signaling properties regarding Kv4.2 phosphorylation at S616. Research demonstrates:

• Shared Signaling Components: All three PAC1 isoforms (Null, Hop1, Hop2) utilize PKC-Ras-MEK1/2 signaling to activate ERK1/2, which subsequently phosphorylates Kv4.2 at S616 .

• Differential Dependence on Arrestin-2: A critical difference exists in arrestin-2 dependence:

  • Hop1 and Hop2 isoforms require arrestin-2 for PACAP-induced ERK1/2 activation

  • The Null isoform can signal independently of arrestin-2

• PKA Involvement: The Null isoform exhibits PKA-dependent ERK1/2 activation, as demonstrated by the attenuation of PACAP-induced ERK1/2 phosphorylation when PKA is inhibited with KT5720 .

This differential signaling is physiologically relevant as the expression pattern of PAC1 isoforms may vary across neuronal populations, potentially contributing to region-specific modulation of Kv4.2 channel function through phosphorylation at S616 and other sites.

What is the relationship between PACAP-induced Kv4.2 phosphorylation and channel internalization?

PACAP-induced Kv4.2 phosphorylation leads to changes in channel surface expression through a complex process of internalization:

• Quantitative Reduction in Surface Expression: Exposure of cultured hippocampal neurons to PACAP27 and PACAP38 (100 nM, 20 min) significantly reduces cell surface Kv4.2 protein levels to 70.35 ± 6% and 80.54 ± 2.24% of untreated control levels, respectively .

• Dual Kinase Dependence: This internalization process requires both:

  • PKA activity (inhibited by KT5720)

  • ERK1/2 activity (inhibited by U0126, a MEK1/2 inhibitor)

• Signaling Convergence: While PKA directly phosphorylates Kv4.2 at S552, the effect of PKA inhibition on PACAP-induced channel internalization suggests that PKA signaling converges with or enhances ERK1/2-mediated phosphorylation at sites including S616 .

• Forskolin Mimicry: Forskolin (10 μM, 20 min), which activates cAMP/PKA, produces similar reductions in surface Kv4.2 levels (64.28 ± 9.16% compared to control), also dependent on both PKA and ERK1/2 activity .

This relationship suggests that PACAP signaling coordinates multiple phosphorylation events on Kv4.2 (including at S616) to regulate channel trafficking and surface expression, ultimately influencing neuronal excitability.

How do phospho-disruptive mutations at S616 affect Kv4.2 channel function and PACAP responsiveness?

Studies using phospho-disruptive mutations provide critical insights into the functional significance of S616 phosphorylation:

• Baseline Electrophysiological Properties: When expressed in HEK293T cells with KChIP2 (an accessory subunit), Kv4.2 channels with phospho-disruptive mutations at the ERK1/2 sites (T602A, T607A, S616A) do not exhibit significant differences in baseline current density compared to wild-type channels .

• PACAP Response in PKA Site Mutant: The PKA phosphorylation site mutant (S552A) still exhibits significant current density reduction following PACAP38 application (100 nM, 20 min), similar to wild-type Kv4.2 .

• ERK1/2 Phosphorylation Site Requirement: Experiments with phospho-disruptive mutations at ERK1/2 sites (including S616) demonstrate that direct phosphorylation of these residues is necessary for PACAP-induced reduction in Kv4.2 currents .

• Convergence of Signaling Pathways: While PKA inhibition with KT5720 attenuates PACAP effects on wild-type channels, the persistent PACAP sensitivity of S552A mutants indicates that PKA's effects likely converge on ERK1/2 activation, ultimately leading to phosphorylation at sites including S616 .

These findings highlight S616 as a critical residue for modulation of Kv4.2 function downstream of PACAP/PAC1 signaling and provide a molecular mechanism for the observed electrophysiological effects.

What are the optimal conditions for using Phospho-KCND2 (S616) antibodies in various applications?

Based on research protocols and technical information, the following conditions are recommended for using Phospho-KCND2 (S616) antibodies in different applications:

When detecting phosphorylated Kv4.2, it is crucial to:

• Include phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride, β-glycerophosphate) in all buffers

• Process samples quickly and maintain cold temperatures to prevent dephosphorylation

• Consider positive controls such as PACAP38 or forskolin-treated neurons to validate antibody performance

How can I design experiments to distinguish between PKA and ERK1/2 effects on Kv4.2 phosphorylation?

Designing experiments to differentiate between PKA and ERK1/2 effects on Kv4.2 phosphorylation requires a multi-faceted approach:

• Pharmacological Inhibitors:

  • PKA inhibition: KT5720 (1 μM)

  • MEK1/2 inhibition (upstream of ERK1/2): U0126 (1 μM)

• Phospho-site Mutants:

  • PKA site mutant: Kv4.2-S552A

  • ERK1/2 site mutants: Kv4.2-T602A, T607A, S616A (individual or combined mutations)

• Pathway-Specific Activators:

  • PKA activation: Forskolin (10 μM)

  • ERK1/2 pathway: PACAP (100 nM) with isoform-specific PAC1 receptors

• Differential Readouts:

  • Metabolic 32P-labeling to measure total phosphorylation

  • Phospho-specific antibodies to detect site-specific phosphorylation

  • Surface expression assays (quantitative on-cell fluorescence immunocytochemistry)

  • Electrophysiological recordings to assess functional outcomes

• Signaling Component Manipulation:

  • Dominant-negative Ras (N17-Ras) to block Ras-dependent ERK1/2 activation

  • siRNA knockdown of arrestin-2 or arrestin-3 to assess their contributions

By combining these approaches, researchers can systematically dissect the roles of PKA and ERK1/2 in Kv4.2 phosphorylation at S616 and other sites, as well as the functional consequences of these modifications.

What metabolic labeling protocols are most effective for studying Kv4.2 phosphorylation dynamics?

The metabolic 32P-labeling approach offers high sensitivity for detecting dynamic phosphorylation of Kv4.2. Based on published protocols, the following methodology is recommended:

• Cell Preparation:

  • Use cultured hippocampal neurons (DIV 12-13) or appropriate expression systems

  • Wash cells thoroughly before labeling to remove excess phosphate

• Labeling Procedure:

  • Incubate cells in phosphate-free RPMI medium

  • Add 1% dialyzed FBS to maintain cell health

  • Include 0.5 mCi·mL−1 32P-labeled orthophosphate

  • Incubate for 4 hours at 37°C to allow incorporation

• Stimulation Protocol:

  • Apply treatments during the final 20 minutes of labeling

  • Recommended treatments: vehicle (control), PACAP38 (100 nM), or forskolin (10 μM)

• Sample Processing:

  • Quickly wash cells with ice-cold PBS

  • Lyse cells in buffer containing phosphatase inhibitors

  • Perform immunoprecipitation with anti-Kv4.2 antibody (5 μg per reaction)

  • Include negative controls such as immunoprecipitation with irrelevant antibodies (e.g., anti-PP2A)

• Analysis:

  • Analyze samples by phosphorimaging to detect 32P incorporation

  • Perform parallel immunoblotting for total Kv4.2

  • Quantify signal intensities using NIH Image J or similar software

  • Calculate phosphorylation level as the ratio of 32P signal to total Kv4.2 protein

This protocol provides a robust measurement of total Kv4.2 phosphorylation changes in response to various stimuli, complementing site-specific analyses with phospho-antibodies.

How should researchers interpret conflicting data between phospho-antibody and functional studies?

When faced with discrepancies between phospho-antibody detection and functional outcomes in Kv4.2 studies, consider the following interpretive framework:

• Temporal Dynamics: Phosphorylation may be transient while functional effects persist longer. Sequential sampling at multiple timepoints (5, 10, 20, 30, 60 minutes) after stimulation can reveal these differences .

• Threshold Effects: There may be a threshold level of phosphorylation required for functional changes. Quantitative analysis comparing phosphorylation levels with functional readouts can reveal non-linear relationships .

• Multiple Phosphorylation Sites: Kv4.2 contains several phosphorylation sites (PKA site S552; ERK1/2 sites T602, T607, S616) that may interact. The functional outcome may depend on the pattern of phosphorylation across multiple sites rather than any single site .

• Phosphorylation-Independent Effects: Some signaling pathways may affect Kv4.2 function independently of direct channel phosphorylation, such as through auxiliary subunits or interacting proteins .

• Technical Considerations:

  • Antibody sensitivity limitations

  • Accessibility of phospho-epitopes in different experimental preparations

  • Potential loss of phosphorylation during sample processing

When conflicts arise, combining multiple approaches (metabolic labeling, phospho-mutants, and electrophysiology) provides the most reliable interpretation of the relationship between Kv4.2 phosphorylation and function.

What are common technical challenges with Phospho-KCND2 (S616) antibodies and how can they be addressed?

Researchers frequently encounter several technical challenges when working with phospho-specific antibodies for Kv4.2:

• Cross-Reactivity Issues:

  • Problem: Phospho-antibodies may recognize similar phosphorylated motifs in other proteins

  • Solution: Validate specificity using phospho-null mutants (S616A) and phosphatase-treated samples as negative controls

• Variable Phosphorylation Levels:

  • Problem: Basal phosphorylation may vary between preparations, obscuring treatment effects

  • Solution: Normalize to total protein; include positive controls (PACAP or forskolin treatment) in each experiment

• Rapid Dephosphorylation:

  • Problem: Phosphorylation can be lost during sample preparation

  • Solution: Maintain samples at 4°C; include phosphatase inhibitor cocktails in all buffers; minimize processing time

• Detection Sensitivity:

  • Problem: Low abundance of phosphorylated species

  • Solution: Enrich target protein by immunoprecipitation before western blotting; use enhanced chemiluminescence or fluorescent secondary antibodies

• Application-Specific Optimization:

  • Problem: Conditions optimal for western blotting may not work for immunofluorescence

  • Solution: Titrate antibody concentrations for each application; optimize fixation and permeabilization protocols specifically for phospho-epitopes

• Batch Variability:

  • Problem: Different antibody lots may show variable sensitivity

  • Solution: Test each new lot against a reference sample; maintain aliquots of positive control samples for standardization

By addressing these challenges methodically, researchers can obtain more reliable and reproducible results with Phospho-KCND2 (S616) antibodies.

What are emerging applications for Phospho-KCND2 (S616) antibodies in neuroscience research?

Phospho-KCND2 (S616) antibodies are becoming increasingly valuable tools in several emerging research areas:

• Synaptic Plasticity Mechanisms: Investigating the role of activity-dependent Kv4.2 phosphorylation in long-term potentiation (LTP) and depression (LTD), particularly in dendritic integration and backpropagation of action potentials .

• Neurodevelopmental Disorders: Examining alterations in Kv4.2 phosphorylation patterns in models of autism, intellectual disability, and epilepsy, where dysregulated ERK1/2 signaling has been implicated .

• Spatiotemporal Signaling Dynamics: Using advanced imaging techniques combined with phospho-specific antibodies to visualize the subcellular localization and temporal dynamics of Kv4.2 phosphorylation in response to various stimuli .

• Proteomic Analysis: Integrating phospho-antibodies with mass spectrometry approaches to identify novel phosphorylation-dependent protein interactions within the Kv4.2 complex .

• Neuronal Excitability in Disease Models: Investigating how pathological conditions alter PACAP/ERK signaling and subsequent Kv4.2 phosphorylation, potentially contributing to hyperexcitability in epilepsy or neurodegenerative disorders .

These applications highlight the continuing importance of phospho-specific antibodies in unraveling the complex regulatory mechanisms governing neuronal excitability and plasticity through Kv4.2 channel modulation.

How does S616 phosphorylation interact with other post-translational modifications of Kv4.2?

Kv4.2 undergoes multiple post-translational modifications that potentially interact with S616 phosphorylation in complex ways:

• Hierarchical Phosphorylation: Evidence suggests that phosphorylation at one site can influence modification at other sites. For example, PKA phosphorylation at S552 may facilitate or prime subsequent ERK1/2-mediated phosphorylation at S616, as suggested by the convergent effects of PKA inhibition on PACAP-induced channel modulation .

• Competing Modifications: Different kinase pathways may compete for access to the channel, with phosphorylation at some sites potentially precluding modification at others due to conformational changes in the protein.

• Scaffold Protein Interactions: KChIPs and other auxiliary subunits may influence the accessibility of various phosphorylation sites, including S616, by altering channel conformation or recruiting specific signaling complexes .

• Integration with Other Modifications: Beyond phosphorylation, Kv4.2 undergoes other modifications such as ubiquitination and SUMOylation, which may interact with phosphorylation status to determine channel fate and function.

• Temporal Sequence: The specific order of modifications may be critical, with early phosphorylation events potentially directing subsequent trafficking, additional modifications, or protein-protein interactions .